$QNTA Big News : Medolife Rx Presents Its Venom-To
Post# of 40256
(Total Views: 157)
Posted On: 01/13/2022 7:17:05 AM
$QNTA Big News : Medolife Rx Presents Its Venom-To-Drug Development Projects at an International Conference Held in the Dominican Republic
BURBANK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"
, a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that the Company’s venom-to-drug project was presented during an international conference organized by the Dominican Republic (“DR”) Ministry of Environment (“MOE”) for projects that utilize natural resources. The conference focused on projects that seek to use natural resources to improve the lives of humans, such as Medolife’s product, Escozine, which is registered as an alternative oncological medicine in the DR, and anticipates seeking approval as a COVID 19 treatment in both the United States, under PIND #150335, and the DR. The peptides obtained from the scorpion venom are used by the Company in combination with their patented polarization technology to create an ever-growing line of drugs and nutraceuticals.
https://finance.yahoo.com/news/medolife-rx-pr...00894.html
BURBANK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"
, a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that the Company’s venom-to-drug project was presented during an international conference organized by the Dominican Republic (“DR”) Ministry of Environment (“MOE”) for projects that utilize natural resources. The conference focused on projects that seek to use natural resources to improve the lives of humans, such as Medolife’s product, Escozine, which is registered as an alternative oncological medicine in the DR, and anticipates seeking approval as a COVID 19 treatment in both the United States, under PIND #150335, and the DR. The peptides obtained from the scorpion venom are used by the Company in combination with their patented polarization technology to create an ever-growing line of drugs and nutraceuticals. https://finance.yahoo.com/news/medolife-rx-pr...00894.html
(0)
(0)Scroll down for more posts ▼